Edition:
United Kingdom

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

162.70EUR
19 Jul 2019
Change (% chg)

€8.70 (+5.65%)
Prev Close
€154.00
Open
€155.20
Day's High
€165.95
Day's Low
€155.00
Volume
1,269,037
Avg. Vol
452,013
52-wk High
€165.95
52-wk Low
€74.48

Latest Key Developments (Source: Significant Developments)

Gilead To Boost Stake In Belgian Biotech Galapagos As Part Of $5.1 Billion Deal - WSJ
Sunday, 14 Jul 2019 

July 14 (Reuters) - :GILEAD TO BOOST STAKE IN BELGIAN BIOTECH GALAPAGOS AS PART OF $5.1 BILLION DEAL - WSJ.GILEAD SCIENCES TO PAY $5.1 BILLION TO BOOST ITS STAKE IN GALAPAGOS AND GAIN RIGHTS OUTSIDE EUROPE TO GALAPAGOS'S TREATMENTS IN DEVELOPMENT - WSJ.GILEAD SCIENCES WILL INVEST $1.1 BILLION, OR €140.59 ($158.49) A SHARE, TO INCREASE ITS STAKE IN GALAPAGOS TO 22% FROM 12.3% - WSJ.  Full Article

Galapagos: Gilead Plans To Submit New Drug Application For Filgotinib To FDA
Tuesday, 2 Jul 2019 

July 2 (Reuters) - Galapagos NV ::GILEAD ANNOUNCES INTENT TO SUBMIT NEW DRUG APPLICATION FOR FILGOTINIB TO U.S. FOOD AND DRUG ADMINISTRATION THIS YEAR.FILGOTINIB IS AN INVESTIGATIONAL AGENT AND NOT APPROVED ANYWHERE GLOBALLY.COMPANY DISCUSSED WITH AGENCY PHASE 3 FINCH STUDIES, AS WELL AS ONGOING PHASE 2 MANTA SAFETY STUDY.AS RESULT OF THIS DISCUSSION, A PATH FORWARD HAS BEEN ESTABLISHED TO SUBMIT NDA FOR FILGOTINIB AS TREATMENT FOR RHEUMATOID ARTHRITIS IN 2019.  Full Article

Galapagos NV Files For Potential Mixed Shelf Offering Size, Not Disclosed
Friday, 29 Mar 2019 

March 29 (Reuters) - Galapagos NV ::GALAPAGOS NV FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Galapagos Increases Share Capital Through Warrant Exercises
Wednesday, 20 Mar 2019 

Mar 21(Reuters) - GALAPAGOS NV ::ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES.ISSUES 149,370 NEW ORDINARY SHARES FOR A TOTAL CAPITAL INCREASE (INCLUDING ISSUANCE PREMIUM) OF 3,480,747.50 EUROS.  Full Article

Galapagos And Fibrocor Sign Partnership Focusing On Fibrosis
Friday, 4 Jan 2019 

7/1/2019(Reuters) - GALAPAGOS ::SAID ON FRIDAY FIBROCOR THERAPEUTICS L.P. AND GALAPAGOS SIGN PARTNERSHIP FOCUSING ON FIBROSIS.IN EXCHANGE FOR GLOBAL COMMERCIALIZATION RIGHTS TO GALAPAGOS, FIBROCOR WILL RECEIVE AN UPFRONT PAYMENT.FIBROCOR WILL POTENTIALLY RECEIVE FURTHER MILESTONE AND ROYALTY PAYMENTS.GALAPAGOS WILL BE RESPONSIBLE FOR ALL FURTHER DEVELOPMENT OF THE PROGRAM.  Full Article

Galapagos Receives Fast Track Designation From FDA For GLPG1972/S201086 In Osteoarthritis
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Galapagos NV ::GALAPAGOS RECEIVES FAST TRACK DESIGNATION FROM FDA FOR GLPG1972/S201086 IN OSTEOARTHRITIS.  Full Article

Galapagos 9-Month Revenue Rises To 205.1 Million Euros
Wednesday, 24 Oct 2018 

Oct 25 (Reuters) - GALAPAGOS ::REPORTED ON WEDNESDAY 9-MONTH GROUP REVENUES INCREASED BY EUR 98.7 MILLION TO EUR 205.1 MILLION.9-MONTH OPERATING LOSS DECREASED BY EUR 9.1 MILLION TO EUR 53.5 MILLION.9-MONTH NET LOSS DECREASED BY EUR 41.7 MILLION TO EUR 44.2 MILLION.CASH AND CASH EQUIVALENTS ON 30 SEPT 2018 OF EUR1,343.7 MILLION.IN Q4, EXPECTS TO PRESENT MORE DETAILED FINDINGS FROM THE EQUATOR, TORTUGA, AND FINCH 2 TRIALS WITH FILGOTINIB.WILL ALSO PRESENT FIRST DATA AND DEVELOPMENT STRATEGY WITH REGARD TO TOLEDO, OUR NEW PROGRAM IN INFLAMMATORY INDICATIONS.EXPECT TO START DOSING IN THE ISABELA (PH3 IPF `1690) AND PINTA (PH2 IPF `1205) PATIENT TRIALS.DUE TO REVISION OF THE ABBVIE COLLABORATION AGREEMENT IN CF, CO IS REDUCING EXPECTED OPERATIONAL CASH BURN FROM THE LAST GUIDED EUR180-200 MILLION TO EUR140-160 MILLION IN 2018.  Full Article

Galapagos Announces Positive Trial Results With Filgotinib In Psoriatic Arthritis And Ankylosing Spondylitis
Monday, 22 Oct 2018 

Oct 22 (Reuters) - GALAPAGOS NV ::REG-POSITIVE TRIAL RESULTS WITH FILGOTINIB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS BOTH PUBLISHED IN THE LANCET.RESULTS OF EQUATOR AND TORTUGA STUDIES DEMONSTRATE THAT FILGOTINIB IMPROVED SIGNS AND SYMPTOMS OF PATIENTS WITH PSORIATIC ARTHRITIS.RESULTS OF EQUATOR AND TORTUGA STUDIES DEMONSTRATE THAT FILGOTINIB IMPROVED SIGNS AND SYMPTOMS OF PATIENTS WITH ANKYLOSING SPONDYLITIS.  Full Article

Galapagos: Capital Increase Of EUR 2.0 Million
Wednesday, 3 Oct 2018 

Oct 4(Reuters) - GALAPAGOS ::ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES.ISSUED 135,485 NEW ORDINARY SHARES ON 3 OCTOBER 2018, FOR A TOTAL CAPITAL INCREASE (INCLUDING ISSUANCE PREMIUM) OF EUR 2,013,590.25.  Full Article

Gilead & Galapagos Announce Filgotinib Meets Primary Endpoint In First Phase 3 Study In Rheumatoid Arthritis
Tuesday, 11 Sep 2018 

Sept 11 (Reuters) - Galapagos NV ::GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN FIRST PHASE 3 STUDY IN RHEUMATOID ARTHRITIS.GALAPAGOS NV - BOTH FILGOTINIB DOSES ALSO ACHIEVED ALL KEY SECONDARY EFFICACY ENDPOINTS.GALAPAGOS NV - TOLERABILITY OF FILGOTINIB WAS CONSISTENT WITH PREVIOUSLY REPORTED STUDIES.GALAPAGOS - FILGOTINIB WAS GENERALLY WELL-TOLERATED IN FINCH 2 TRIAL, WITH NO NEW SAFETY SIGNALS VERSUS THOSE REPORTED IN PREVIOUS TRIALS OF FILGOTINIB.  Full Article

Photo

Gilead invests $5 billion to deepen ties with biotech Galapagos

U.S. antiviral drugmaker Gilead Sciences will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV , news that lifted Galapagos's shares more than 18% to an all-time high on Monday.